Back to Journals » Drug Design, Development and Therapy » Volume 12

The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease

Authors Zhong H, Zhou T, Li H, Zhong Z

Received 31 May 2018

Accepted for publication 6 August 2018

Published 18 September 2018 Volume 2018:12 Pages 3003—3011

DOI https://doi.org/10.2147/DDDT.S175887

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Manfred Ogris


Hongzhen Zhong,1,* Tianbiao Zhou,1,* Hongyan Li,2,* Zhiqing Zhong1,*


1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China; 2Department of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical University, Guangzhou, China


*These authors contributed equally to this work


Introduction: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients.
Methods: Published studies were extracted from PubMed, China Biological Medicine Database (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant studies were pooled and included in a meta-analysis. Data on hemoglobin (Hb), ferritin, and hepcidin levels, total iron-binding capacity (TIBC), and incidence of adverse events (AEs) were extracted and pooled using Review Manager Version 5.3.
Results: Data from nine selected studies were extracted. Meta-analysis of the included studies showed that HIF stabilizers reduced ferritin and hepcidin levels and increased Hb level and TIBC in NDD-CKD patients. However, HIF stabilizers only increased TIBC, and did not affect ferritin, hepcidin, and Hb levels in DD-CKD patients. Furthermore, no notable differences in AEs and severe AEs between NDD-CKD and DD-CKD patients were detected.
Conclusion: HIF stabilizers are effective for the treatment of anemia in NDD-CKD patients and safe for short-term use.


Keywords: hypoxia-inducible factor stabilizer, anemia, chronic kidney disease, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]